United Therapeutics Corp (UTHR)

Jun 17, 2025

United Therapeutics delivers 18th consecutive quarter of topline growth - MarketScreener

Jun 17, 2025

Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock By Investing.com - Investing.com Canada

Jun 16, 2025

Jun 16, 2025

United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing - MarketScreener

Jun 16, 2025

Jun 16, 2025

United Therapeutics EVP Paul Mahon sells $3.08m in stock - Investing.com

Jun 16, 2025

Jun 15, 2025

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio? - Benzinga

Jun 15, 2025

Jun 11, 2025

United Therapeutics (UTHR) Maintains Neutral Rating, Price Targe - GuruFocus

Jun 11, 2025

Jun 10, 2025

Insmed Shares Rise After Phase 2b Trial of Treprostinil Inhalation Powder in PAH Meets Endpoints - marketscreener.com

Jun 10, 2025

Jun 10, 2025

United Therapeutics (UTHR) Stock Plummets Over 15% in Major Sell-Off - Daily Chhattisgarh News

Jun 10, 2025

Jun 06, 2025

Treprostinil Saga Continues - JD Supra

Jun 06, 2025

Jun 06, 2025

United Therapeutics president sells shares worth $3.7 million - MSN

Jun 06, 2025

Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock By Investing.com - Investing.com South Africa

Jun 04, 2025

Jun 04, 2025

Leerink Partners maintains positive outlook on United Therapeutics stock - Investing.com

Jun 04, 2025

Jun 03, 2025

United Therapeutics (NASDAQ:UTHR) Now Covered by Cantor Fitzgerald - Defense World

Jun 03, 2025

Jun 02, 2025

United Therapeutics (UTHR) Receives New Overweight Rating from C - GuruFocus

Jun 02, 2025

Jun 02, 2025

Forecasting The Future: 7 Analyst Projections For United Therapeutics - Benzinga

Jun 02, 2025

Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Canto - GuruFocus

Jun 02, 2025

Jun 02, 2025

United Therapeutics (UTHR) Receives Overweight Rating from Cantor Fitzgerald | UTHR Stock News - GuruFocus

Jun 02, 2025

May 29, 2025

Ex-United Therapeutics Exec Can't Dodge IP Suit - Law360

May 29, 2025

May 29, 2025

United Therapeutics Co. (NASDAQ:UTHR) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

May 29, 2025

May 29, 2025

Those who invested in United Therapeutics (NASDAQ:UTHR) five years ago are up 151% - Yahoo

May 29, 2025

May 27, 2025

Liquidia Scores FDA Nod For Lung Disease Drug Yutrepia, Faces Legal Challenge - Benzinga

May 27, 2025

May 27, 2025

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance

May 27, 2025

May 26, 2025

Eisenmenger Complex Treatment Market 2032: EMA, PDMA, FDA Approvals, Medication, NICE Approvals, Clinical Trials, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - Barchart.com

May 26, 2025

May 24, 2025

FDA Approves Liquidia Corporation (LQDA)’s YUTREPIA Amid Patent Dispute - Insider Monkey

May 24, 2025

May 24, 2025

Zacks Research Has Pessimistic Outlook of UTHR Q2 Earnings - Defense World

May 24, 2025

May 23, 2025

FDA Approves Liquidia's (LQDA) Yutrepia, Court Ruling Pending - GuruFocus

May 23, 2025

May 23, 2025

Zacks Research Issues Negative Estimate for UTHR Earnings - Defense World

May 23, 2025

May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025

May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025

May 15, 2025

Construction underway for new United Therapeutics facility in Stewartville - KTTC News

May 15, 2025

May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025

May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025

May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025

May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025

May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025

May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025

May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025

May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025

May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025

May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025

May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025

May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025

May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025

May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025

May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025

May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025

May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025

May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025

May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025

May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025